Making lung tumors glow with the imaging agent pafolacianine leads to more thorough resections, trial data show; however, there s no survival data yet.
New guidance on the use of definitive local therapy to treat patients with oligometastatic non–small cell lung cancer has been issued by the American Society for Radiation Oncology and European Society for Radiotherapy and Oncology.
Researchers highlight improvements that are needed in cancer prevention, detection, and treatment in order to meet President Joe Biden s goal of a 50% reduction in cancer mortality in 25 years’ time.
The AEGEAN trial is the second phase 3 study, after Checkmate 816, to demonstrate a benefit from neoadjuvant immunotherapy for patients with resectable non–small cell lung cancer.